← Back to all articles
PharmacologyPubMed VerifiedOpen Access

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects

Abelo A, Smallridge JW, Von Rotz R, Egger K, Scheidegger M

Biomedicine & Pharmacotherapy (2025)

Pharmacokinetic modeling
Abstract

Pharmacokinetic modeling in 16 healthy participants demonstrated that harmine markedly enhances DMT bioavailability and prolongs absorption via buccal delivery. Revealed substantial inter-individual variability in drug sensitivity and clearance.

Participants16
Study TypePharmacokinetic modeling
population PK-PDmodelingDMTharminebuccal deliveryvariability
DOI: 10.1016/j.biopha.2025.118329View on PubMed

Related Articles

Pharmacology

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: a factorial dose-escalation study

Egger K, Jareno Redondo J et al.

Biomedicine & Pharmacotherapy, 2025
Pharmacology

Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans

Wittayakarn N, Tan YM et al.

Toxicological Sciences, 2025
Pharmacology

Dimethyltryptamine and harmine, components of ayahuasca, prevented cocaine-induced apoptosis in SH-SY5Y human neuroblastoma cells

Salles G, de Carvalho Alves I et al.

Archives of Toxicology, 2025
Pharmacology

Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects

Aicher HD, Mueller MJ et al.

Frontiers in Psychiatry, 2024